Summary of Pro Pharmaceutical Conference Call Company Overview - Pro Pharmaceutical is experiencing rapid expansion in its CDMO (Contract Development and Manufacturing Organization) business, with over 600 R&D personnel in Shanghai and Hengdian, expected to exceed 1,000 in the next two years [2][4] - The R&D pipeline has grown from 28 API (Active Pharmaceutical Ingredient) projects in 2021 to 79 expected by 2024, with 22 commercialized API projects and 15 in the validation stage [2][4] Core Insights and Arguments - The CDMO revenue primarily comes from overseas business, accounting for over half of the total revenue, providing stable income growth and supporting overall performance [2][4] - Domestic formulation business is anticipated to enter a rapid growth phase by 2026, with an integrated business model and a multi-product strategy expected to yield over 15 approvals annually [2][5] - The raw material drug segment is showing a stable upward trend, with prices of antibiotics like cephalosporins expected to rebound after reaching a low point, and expansion in chronic disease raw materials expected to sustain long-term growth [2][7] - Key products like florfenicol are nearing price stabilization, which may enhance profit margins; the aesthetic medicine raw materials sector is expected to grow rapidly through diversified layouts and partnerships with leading cosmetics companies [2][7] Additional Important Points - Pro Pharmaceutical is investing in high-tech modified new drugs to achieve differentiated competition [5][6] - The overall outlook for Pro Pharmaceutical suggests a projected P/E ratio of approximately 10 by 2027, indicating investment value [3][8] - The three main business segments (CDMO, formulation, and raw materials) are expected to enter a new growth cycle starting in 2026, with a compound annual growth rate (CAGR) of over 20% anticipated in the coming years [3][8]

Group 1 - The company announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 8, 2025 [2] - The meeting will review and approve several proposals, including the adjustment of the composition of the company's board of directors and its specialized committees [2]

Group 1 - The core point of the article is that Pro Pharmaceutical announced the approval of several proposals, including the adjustment of the members of its board committees during the 15th meeting of the 9th board of directors [2] Group 2 - The announcement was made on the evening of September 8 [2] - The adjustments pertain to the company's specialized committees within the board [2] - The meeting reflects ongoing governance and structural changes within the company [2]

Core Viewpoint - Pro Pharmaceutical announced the election of Mr. Shi Xinyue as the employee representative director of the company's ninth board of directors during the second employee representative assembly held on September 8, 2025 [1] Summary by Relevant Sections - **Company Governance** - The second employee representative assembly of Pro Pharmaceutical was held on September 8, 2025, where Mr. Shi Xinyue was elected as the employee representative director [1] - The newly elected board will work alongside the non-employee representative directors elected by the shareholders [1] - The term for the newly elected board members will last until the end of the ninth board's term [1]

证券代码：000739 证券简称：普洛药业 公告编号：2025-50 普洛药业股份有限公司董事会 2025 年 9 月 8 日 附：个人简历 石新跃先生:1973 年出生，本科学历，高级会计师。曾任横店集团东磁股份有限公司下 属企业财务科长兼主办会计；横店技校老师；浙江优胜美特中药有限公司财务经理；安徽普 洛生物科技有限公司财务经理；本公司财务主管；现任公司财务部副部长、工会副主席。 石新跃先生直接持有本公司股票 0 股，与持有公司 5%以上股份的股东、实际控制人、 公司其他董事、高级管理人员之间无关联关系；未受过中国证监会及其他有关部门的处罚和 证券交易所纪律处分，未因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步完善公司治理结构，根据《中华人民共和国公司法》《深圳证券交 易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市 公司规范运作》等相关法律法规和《公司章程》的规定，普洛药业股份有限公司 （以下简称"公司"）于2025年9月8日召开公司 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-49 普洛药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未有否决议案。 （1）现场会议召开时间：2025 年 9 月 8 日下午 14:30 （2）网络投票时间：2025 年 9 月 8 日 2、本次股东大会未涉及变更以往股东大会已通过的决议。 3、根据国家有关法律、法规等相关规定，上市公司回购专用证券账户所持 股份不享有股东大会的表决权，公司现有总股本1,158,443,576股，截至本次股 东大会股权登记日，公司回购专用证券账户持有公司股份10,030,000股，故公司 本次股东大会有表决权股份总数为1,148,413,576股。 一、会议召开和出席情况 1、召集人：公司第九届董事会 2、主持人：公司董事长 祝方猛先生 3、会议召开方式：现场投票与网络投票相结合 4、会议召开时间： 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 8 日：9:15—9:25，9:30—11:3 ...

康大律师事务所 ANGDA LAW FIRM 北京市朝阳区建外大街丁 12号英皇集团中心 8、9、11层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022. P.R.China 电话/Tel .: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于普洛药业股份有限公司 2025 年第一次临时股东大会的法律意见书 康达股会字【2025】第 0364 号 致:普洛药业股份有限公司 北京市康达律师事务所(以下简称"本所")接受普洛药业股份有限公司(以 下简称" 公司")的委托,指派本所律师参加公司 2025 年第一次临时股东大会(以 下简称"本次会议")。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-51 普洛药业股份有限公司 调整后，公司第九届董事会各专门委员会成员如下： 1、董事会战略与 ESG 委员会 委员：祝方猛、徐文财、胡天高、厉宝平（个人简历附后）、陈凌 主任委员：祝方猛 2、董事会审计委员会 委员：徐文财（个人简历附后）、钱娟萍、潘伟光 第九届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）第九届董事会第十五次会议通 知于2025年8月29日以短信的方式发出。会议于2025年9月8日下午在公司会议室 通过现场方式召开，本次会议由董事长祝方猛先生主持。会议应出席董事9名， 实际出席董事9名。本次会议的召开符合《公司法》和《公司章程》的有关规定。 经与会董事审议表决，会议形成如下决议： 一、审议通过《关于调整公司董事会各专门委员会委员的议案》 鉴于公司调整了董事会及其各专门委员会成员构成，公司董事会成员由七名 调整为九名（增加一名非独立董事和一名职工代表董事），董事会战略与 ESG 委员会成员由七名调整为五名，董事会 ...

Core Viewpoint - The company emphasizes that its market value is influenced by various factors including macroeconomic environment, policy landscape, industry cycles, and operational performance [1] Group 1 - The company adheres to the principles of value creation and value sharing [1] - The company is committed to creating greater value for customers, employees, shareholders, and society [1]

Group 1 - The core viewpoint of the article is that the company's CDMO business is outperforming its API business, indicating a shift in growth dynamics [1] - The API business is currently at the bottom of the industry cycle, leading to year-on-year performance pressure [1] - The CDMO business is entering a harvest phase, which is expected to drive the company's performance into a new growth stage [1]